| 000 | 01805 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518024104.0 | ||
| 264 | 0 | _c20200708 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a2366-0058 | ||
| 024 | 7 |
_a10.1007/s00261-019-01935-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlessandrino, Francesco | |
| 245 | 0 | 0 |
_aFrequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. _h[electronic resource] |
| 260 |
_bAbdominal radiology (New York) _c05 2019 |
||
| 300 |
_a1917-1927 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 |
_aBiliary Tract Diseases _xchemically induced |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorodeoxyglucose F18 |
| 650 | 0 | 4 |
_aGastrointestinal Diseases _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNivolumab _xadverse effects |
| 650 | 0 | 4 | _aPositron Emission Tomography Computed Tomography |
| 650 | 0 | 4 | _aRadiography, Abdominal |
| 650 | 0 | 4 | _aRadiopharmaceuticals |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 700 | 1 | _aSahu, Sonia | |
| 700 | 1 | _aNishino, Mizuki | |
| 700 | 1 | _aAdeni, Anika E | |
| 700 | 1 | _aTirumani, Sree Harsha | |
| 700 | 1 | _aShinagare, Atul B | |
| 700 | 1 | _aAwad, Mark M | |
| 773 | 0 |
_tAbdominal radiology (New York) _gvol. 44 _gno. 5 _gp. 1917-1927 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00261-019-01935-2 _zAvailable from publisher's website |
| 999 |
_c29397950 _d29397950 |
||